Areas of Interest: Solid tumor immunotherapy, pancreatic cancer, stromal modulation, pharmacodynamic tolerance and drug resistance, cellular plasticity and epithelial-to-mesenchymal transformation.
Ph.D., The State University of New York – University at Buffalo (SUNY Buffalo) B.S., St. John Fisher University
Dr. Perri is a Visiting Assistant Professor at the Department of Pharmaceutical Sciences at St. John Fisher University, Wegmans School of Pharmacy. He received his Ph.D. in Pharmaceutical Sciences from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences, studying mechanisms of pharmacodynamic tolerance to stromal inhibitors in pancreatic cancer and developing lipid nanoparticle-based immunotherapies. His research is now focused on understanding cellular plasticity in response to inhibitors of the sonic hedgehog signaling pathway and mapping cell-cell interactions between pancreatic cancer cells, immune cells, and stromal fibroblasts. In addition to research, Dr. Perri is a 2024 fellow of the American Foundation for Pharmaceutical Education (AFPE).
At Fisher, Dr. Perri is involved in teaching the following courses for both on-campus and online pathway programs:
PHAR 3148 – Biosystems I (Fall)
PHAR 3144 – Systems Pharmacology I ( Fall)
PHAR 3240 – Biosystems II (Spring)
PHAR 4244 – Systems Pharmacology IV
JonathanPerriVisiting Assistant Professor of PharmacologyWEGPHR 339jperri@sjf.edu(585) 899-3716/media/sized-image-library/headshots-160-x-160/generic-profile.pngDr. Perri is a Visiting Assistant Professor at the Department of Pharmaceutical Sciences at St. John Fisher University, Wegmans School of Pharmacy. He received his Ph.D. in Pharmaceutical Sciences from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences, studying mechanisms of pharmacodynamic tolerance to stromal inhibitors in pancreatic cancer and developing lipid nanoparticle-based immunotherapies. His research is now focused on understanding cellular plasticity in response to inhibitors of the sonic hedgehog signaling pathway and mapping cell-cell interactions between pancreatic cancer cells, immune cells, and stromal fibroblasts. In addition to research, Dr. Perri is a 2024 fellow of the American Foundation for Pharmaceutical Education (AFPE).
At Fisher, Dr. Perri is involved in teaching the following courses for both on-campus and online pathway programs:
PHAR 3148 – Biosystems I (Fall)
PHAR 3144 – Systems Pharmacology I ( Fall)
PHAR 3240 – Biosystems II (Spring)
PHAR 4244 – Systems Pharmacology IV
Ph.D., The State University of New York – University at Buffalo (SUNY Buffalo)B.S., St. John Fisher UniversitySolid tumor immunotherapy, pancreatic cancer, stromal modulation, pharmacodynamic tolerance and drug resistance, cellular plasticity and epithelial-to-mesenchymal transformation.
